Spinal Muscular Atrophy Type II: Clinical Trials

1 trial for Spinal Muscular Atrophy Type II, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Active not recruiting 1

Follow Spinal Muscular Atrophy Type II: new trials by email Literature Review of Spinal Muscular Atrophy Type II trials Research Report on Spinal Muscular Atrophy Type II

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
Onasemnogene Abeparvovec-xioi - Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II
Phase 3Active not recruitingNovartis Gene Therapies852020-02-102026-09-24

Narrower conditions

Spinal Muscular Atrophies of Childhood (1)

Broader conditions

Central Nervous System Diseases (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, Inborn (1)  ·  Heredodegenerative Disorders, Nervous System (1)  ·  Motor Neuron Disease (1)  ·  Muscular Atrophy, Spinal (1)  ·  Nervous System Diseases (1)  ·  Neurodegenerative Diseases (1)  ·  Neuromuscular Diseases (1)  ·  Spinal Cord Diseases (1)

Interventions

Zolgensma (1)

Sponsors

Novartis Gene Therapies (1)

Countries

Australia (1)  ·  Belgium (1)  ·  Canada (1)  ·  France (1)  ·  Italy (1)  ·  Japan (1)  ·  Taiwan (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Sitra Tauscher-Wisniewski, MD (1)

Results publications

PMID 34383289

NIH funding

2019 (1)